Evidence mapPaperPMID 37685845Full record

ReviewInternational journal of molecular sciences2023

Insight into the Molecular Mechanism of Diabetic Kidney Disease and the Role of Metformin in Its Pathogenesis.

Marcin Kleibert, Przemysław Zygmunciak, Klaudia Łakomska, Klaudia Mila, Wojciech Zgliczyński, Beata Mrozikiewicz-Rakowska

Open access · goldFull text readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Marcin KleibertChair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, 02-097 Warsaw, Poland.ORCID 0000-0003-1562-8450
Przemysław ZygmunciakFaculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Klaudia ŁakomskaFaculty of Medicine, Wroclaw Medical University, 50-367 Wroclaw, Poland.
Klaudia MilaFaculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
Wojciech ZgliczyńskiDepartment of Endocrinology, Centre of Postgraduate Medical Education, Bielanski Hospital, 01-809 Warsaw, Poland.
Beata Mrozikiewicz-RakowskaDepartment of Endocrinology, Centre of Postgraduate Medical Education, Bielanski Hospital, 01-809 Warsaw, Poland.
Medical University of Warsaw · PLGrochowski Hospital · PLWroclaw Medical University · PL

Funding

Ministry of Science and Education SKN/SP/534378/2022
6 · The paper itself

Abstract

Diabetic kidney disease (DKD) is one of the leading causes of death among patients diagnosed with diabetes mellitus. Despite the growing knowledge about the pathogenesis of DKD, we still do not have effective direct pharmacotherapy. Accurate blood sugar control is essential in slowing down DKD. It seems that metformin has a positive impact on kidneys and this effect is not only mediated by its hypoglycemic action, but also by direct molecular regulation of pathways involved in DKD. The molecular mechanism of DKD is complex and we can distinguish polyol, hexosamine, PKC, and AGE pathways which play key roles in the development and progression of this disease. Each of these pathways is overactivated in a hyperglycemic environment and it seems that most of them may be regulated by metformin. In this article, we summarize the knowledge about DKD pathogenesis and the potential mechanism of the nephroprotective effect of metformin. Additionally, we describe the impact of metformin on glomerular endothelial cells and podocytes, which are harmed in DKD.

Indexed as

Diabetes MellitusDiabetic NephropathiesMetforminEndothelial CellsHumansHypoglycemic AgentsKidneyHypoglycemic AgentsMetforminAGE pathwaydiabetic kidney diseasehexosamine pathwaymetforminpathogenesisPKC pathwaypolyol pathway

Identifiers

PMID37685845
PMCPMC10487922
OpenAlexW4386073237

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.